Please use this identifier to cite or link to this item:
Title: Predictors of remission in the treatment of major depressive disorder: real-world evidence from a 6-month prospective observational study 
Author: Novick, Diego
Hong, Jihyung
Montgomery, William
Dueñas, Héctor
Gado, Magdy
Haro Abad, Josep Maria
Keywords: Antidepressius
Receptors de serotonina
Orient Mitjà
Serotonin receptors
Middle East
Issue Date: 22-Jan-2015
Publisher: Dove Medical Press
Abstract: BACKGROUND: This study examined potential predictors of remission among patients treated for major depressive disorder (MDD) in a naturalistic clinical setting, mostly in the Middle East, East Asia, and Mexico. METHODS: Data for this post hoc analysis were taken from a 6-month prospective, noninterventional, observational study that involved 1,549 MDD patients without sexual dysfunction at baseline in 12 countries worldwide. Depression severity was measured using the Clinical Global Impression of Severity and the 16-item Quick Inventory of Depressive Symptomatology Self-Report (QIDS-SR16). Depression-related pain was measured using the pain-related items of the Somatic Symptom Inventory. Remission was defined as a QIDS-SR16 score ≤5. Generalized estimating equation regression models were used to examine baseline factors associated with remission during follow-up. RESULTS: Being from East Asia (odds ratio [OR] 0.48 versus Mexico; P<0.001), a higher level of depression severity at baseline (OR 0.77, P=0.003, for Clinical Global Impression of Severity; OR 0.92, P<0.001, for QIDS-SR16), more previous MDD episodes (OR 0.92, P=0.007), previous treatments/therapies for depression (OR 0.78, P=0.030), and having any significant psychiatric and medical comorbidity at baseline (OR 0.60, P<0.001) were negatively associated with remission, whereas being male (OR 1.29, P=0.026) and treatment with duloxetine (OR 2.38 versus selective serotonin reuptake inhibitors, P<0.001) were positively associated with remission. However, the association between Somatic Symptom Inventory pain scores and remission no longer appeared to be significant in this multiple regression (P=0.580), (P=0.008 in descriptive statistics), although it remained significant in a subgroup of patients treated with selective serotonin reuptake inhibitors (OR 0.97, P=0.023), but not in those treated with duloxetine (P=0.182). CONCLUSION: These findings are largely consistent with previous reports from the USA and Europe. They also highlight the potential mediating role of treatment with duloxetine on the negative relationship between depression-related pain and outcomes of depression.
Note: Reproducció del document publicat a:
It is part of: Neuropsychiatric Disease And Treatment, 2015, vol. 11, p. 197-205
Related resource:
ISSN: 1176-6328
Appears in Collections:Articles publicats en revistes (Psicologia Clínica i Psicobiologia)

Files in This Item:
File Description SizeFormat 
649069.pdf252.68 kBAdobe PDFView/Open

This item is licensed under a Creative Commons License Creative Commons